Investors / United States / Catalio Capital Management
Catalio Capital Management
Venture capital · New York, NY, United States · North America
Catalio Capital Management is a New York based investment firm focused on healthcare and AI investing across private, public and credit markets. It runs private equity, structured opportunities (senior-secured financing), public equities long/short and co-investment strategies.
Invests inHealthcare & Biotech
In its own wordshealthcarelife sciencesbiotechaipublic equitiesprivate credit
Your fit with Catalio Capital Management
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCatalio Capital Management lists 114 checked portfolio companies on its own site and is named in 28 funding rounds, 8 of them as lead. Its most frequent entry is Series B, 48% of the companies with a known first round. Its largest themes are Healthcare & Biotech (93%), AI & Machine Learning (3%) and Media & Entertainment (2%). 88% of its companies are based in United States. It invests most often alongside General Catalyst, RA Capital and Andreessen Horowitz.
Counts come from funding rounds that name Catalio Capital Management, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Catalio Capital Management's whole history. Rounds on record name 27 companies; its own site lists 114. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundCatalio Capital Management does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 4% |
| Seed | 0% |
| Series A | 9% |
| Series B | 48% |
| Growth | 39% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 1 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 10 | 2 |
| '26 | 17 | 6 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 96th | 114 companies |
| Recent activity | 98th | 17 rounds in 12 months |
| Early stage | 54th | 4% of entries at pre-seed or seed |
| Evidence | 92th | 20% of companies confirmed by a round |
| Sector focus | 96th | 93% in its largest sector |
| Reach | 88th | 7 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| General Catalyst | 12 |
| RA Capital | 11 |
| Andreessen Horowitz | 8 |
| Casdin Capital | 8 |
| Sanofi Ventures | 8 |
| Lux Capital | 7 |
| ARCH Venture Partners | 6 |
| GV | 5 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11197%
- No longer answers00%
- Points to another company33%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 93% | 15% |
| AI & Machine Learning | 3% | 18% |
| Media & Entertainment | 2% | 4% |
| Fintech | 1% | 12% |
| Industrial & Manufacturing | 1% | 7% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with General Catalyst
Compare Catalio Capital Management head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
from public registers and its siteRecent portfolio activity
when companies last raised with Catalio Capital Management| Date | Company | Stage |
|---|---|---|
| 23 Oct 2026 | Series C+ | |
| 24 Sept 2026 | Series C+ | |
| 23 Sept 2026 | Series C+ | |
| 23 Sept 2026 | Series C+ Led | |
| 17 Sept 2026 | Series B Led | |
| 31 Jul 2026 | Series C+ | |
| 28 Jul 2026 | Series B Led | |
| 15 Jul 2026 | Series C+ |
Round details for Catalio Capital Management
Amounts, full round histories and every co-investor in Catalio Capital Management's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
114 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Portfolio page | ||||
| Abridge develops and provides generative AI for clinical conversations and documentation in healthcare. | Healthcare & BiotechAI & Machine Learning | Portfolio page | ||
| AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| Alentis Therapeutics is a clinical-stage biotech company that treats cancer and reverses fibrosis by developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies | Healthcare & Biotech | Portfolio page | ||
| Amalgam Rx develops digital products and solutions for healthcare, including clinical AI and EHR solutions | Healthcare & Biotech | Aug 2025Debt | Page + round | |
| The company is dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with difficult-to-treat diseases, beginning with cancers. | Healthcare & Biotech | Portfolio page | ||
| The company develops mental health treatments | Healthcare & Biotech | Portfolio page | ||
| Audicus sells online hearing aids and provides audiology services | Healthcare & Biotech | Portfolio page | ||
| The company provides lab automation solutions, including software and hardware platforms for laboratories. | Healthcare & Biotech | Portfolio page | ||
| Avalyn Pharma develops inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. | Healthcare & Biotech | Portfolio page | ||
| Avava is pioneering advanced skin treatments that deliver precision skin renewal with Focal Point Technology for all patients. | Healthcare & Biotech | Sept 2026Series B | Page + round | |
| Aviceda Therapeutics develops novel therapies to improve the lives of patients with immune-mediated diseases | Healthcare & Biotech | Portfolio page | ||
| Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| Axena Health is focused on providing innovative new treatments in women’s pelvic health | Healthcare & Biotech | Portfolio page | ||
| Basecamp Research designs and develops therapeutic models and medicines using artificial intelligence | Healthcare & BiotechAI & Machine Learning | Sept 2026Series C+ | Page + round | |
| Bayesian Health develops a real-time clinical intelligence platform for proactive patient care | Healthcare & Biotech | Jul 2021Round | Page + round | |
| Beacon Biosignals uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics | Healthcare & Biotech | Nov 2025Series B | Page + round | |
| The company provides online nutrition therapy with registered dietitians, covering various health conditions such as weight loss, diabetes, and PCOS. | Healthcare & Biotech | Portfolio page | ||
| BigHat Biosciences designs and develops therapeutics by integrating AI with autonomous generation of biological data. | Healthcare & Biotech | Sept 2026Series C+ | Page + round | |
| Blackrock Neurotech develops neurotechnology that improves patients' lives, particularly those with paralysis and other neurological disorders. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- cataliocapital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 12 Jul 2021
- Companies checked
- 114
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Catalio Capital Management's profile as data
Pull Catalio Capital Management's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/cataliocapital.com
# also
GET /v1/firms/cataliocapital.com/portfolio
GET /v1/firms/cataliocapital.com/coinvestors
GET /v1/firms/cataliocapital.com/news